Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronidazole and probiotic prophylaxis for radiotherapy-induced intestinal complications in prostate cancer
IRCT20200825048515N86Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of metronidazole in prostate cancer (PCa) (3 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Intestinal complications. Started Nov 2025; status: completed.
02
Drugs
metronidazole
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on IRCT20200825048515N86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200825048515N86.